Innovating Works

ASTELLAS

Desconocido
ADAPT-SMART: Accelerated Development of Appropriate Patient Therapies a Sustainable Multi stakeholder Approach... ASTELLAS PHARMA EUROPE LTD participó en un H2020: H2020-JTI-IMI2-2015-04-two-stage-Master Progress in the life sciences and related technologies offer great potential for therapeutic benefits to patients in need. However, major ad...
2015-09-02 - 2018-04-30 | Financiado
CLOSPORE: UNDERSTANDING THE CLOSTRIDIUM SPORE A PREREQUISTE FOR DISEASE INTERVENTIONS AND EXPLOITATION ASTELLAS PHARMA EUROPE LTD participó en un H2020: H2020-MSCA-ITN-2014 Bacterial endospores are the most resistant life-forms on earth and the most important single feature of the genus Clostridium. Thus, whilst...
2014-12-16 - 2018-12-31 | Financiado
DRIVE-AB: DRIVING RE-INVESTMENT IN R&D AND RESPONSIBLE ANTIBIOTIC USE ASTELLAS PHARMA EUROPE LTD participó en un FP6: Antimicrobial resistance (AMR) is widespread. Its global human and economic burden is tremendous and increasing annually. Yet today only a f...
2014-10-01 - 2017-12-31 | Financiado
DRIVE-AB: DRIVING RE INVESTMENT IN R D AND RESPONSIBLE ANTIBIOTIC USE ASTELLAS PHARMA EUROPE LTD participó en un FP7: Antimicrobial resistance (AMR) is widespread. Its global human and economic burden is tremendous and increasing annually. Yet today only a f...
Financiado
BIO-DrIM: Personalized minimization of immunosuppression after solid organ transplantation by biomarker driven... ASTELLAS PHARMA EUROPE LTD participó en un FP7: Organ transplantation has emerged as the gold standard therapy for end-stage organ failure. Incomplete control of chronic allograft injury b...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.